175 related articles for article (PubMed ID: 29124542)
1. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.
Blatt AJ; Kennedy R; Luff RD; Austin RM; Rabin DS
Cancer Cytopathol; 2015 May; 123(5):282-8. PubMed ID: 25864682
[TBL] [Abstract][Full Text] [Related]
3. HPV Cotesting of Unsatisfactory Papanicolaou Tests: Implications for Follow-up Intervals.
Chen F; Hsu Lin L; Hindi I; Sun W; Shafizadeh N; Szeto O; Brandler TC; Simsir A
Am J Clin Pathol; 2023 Aug; 160(2):137-143. PubMed ID: 37052613
[TBL] [Abstract][Full Text] [Related]
4. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.
MacLaughlin KL; Jacobson RM; Radecki Breitkopf C; Wilson PM; Jacobson DJ; Fan C; St Sauver JL; Rutten LJF
J Womens Health (Larchmt); 2019 Feb; 28(2):244-249. PubMed ID: 30614380
[TBL] [Abstract][Full Text] [Related]
5. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
6. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
8. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
[TBL] [Abstract][Full Text] [Related]
9. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
[TBL] [Abstract][Full Text] [Related]
10. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
11. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
12. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies.
Liang LA; Einzmann T; Franzen A; Schwarzer K; Schauberger G; Schriefer D; Radde K; Zeissig SR; Ikenberg H; Meijer CJLM; Kirkpatrick CJ; Kölbl H; Blettner M; Klug SJ
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):474-484. PubMed ID: 33187968
[TBL] [Abstract][Full Text] [Related]
13. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
14. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States.
Kaufman HW; Alagia DP; Chen Z; Onisko A; Austin RM
Am J Clin Pathol; 2020 Sep; 154(4):510-516. PubMed ID: 32637991
[TBL] [Abstract][Full Text] [Related]
15. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
Zhou H; Mody RR; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR; Ge Y
Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
[TBL] [Abstract][Full Text] [Related]
17. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
19. Trends of human papillomavirus testing in cervical cancer screening at a large academic cytology laboratory.
Phelan DF; Boitnott JK; Clark DP; Dubay LC; Gravitt PE
Obstet Gynecol; 2011 Aug; 118(2 Pt 1):289-295. PubMed ID: 21775844
[TBL] [Abstract][Full Text] [Related]
20. Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.
Saraiya M; Benard VB; Greek AA; Steinau M; Patel S; Massad LS; Sawaya GF; Unger ER
Am J Obstet Gynecol; 2014 Oct; 211(4):354.e1-6. PubMed ID: 24813971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
